- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 90,290 | 25.06.24 09:48:45 | -0,500 | -0,55% | 90,830 | 90,880 | 90,870 | 90,790 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 986,000 | 25.06.24 08:13:49 | +1,400 | +0,14% | 981,000 | 992,600 | 986,000 | 984,600 |
